image: Figure 1. Comparison of senescence with frailty in breast cancer and bone marrow transplant survivors. Whole blood from breast cancer (BC) survivors or hematologic malignancy patients treated with allogeneic hematopoietic cell transplantation (HCT) was used to CD3+ peripheral blood mononuclear cells (PBMCs) by magnetic bead purification. Total RNA was used to quantify expression of the cellular senescence marker p16INK4a by qPCR. Expression was normalized to 18S. Values represent the median with 95% confidence interval. Students unpaired two-tailed t test. ** p<0.01, ns (not significant).
Credit: 2024 Jurdi et al.
“Our study highlights the high prevalence of frailty in survivors with detrimental effects on physical and overall wellbeing, and supports an association between frailty and the senescence marker p16INK4a.”
BUFFALO, NY- October 2, 2024 – A new research paper was published on the in Aging (listed by MEDLINE/PubMed as “Aging (Albany NY)” and “Aging-US” by Web of Science), Volume 16, Issue 18 on September 26, 2024, entitled, “Frailty and pre-frailty associated with long-term diminished physical performance and quality of life in breast cancer and hematopoietic cell transplant survivors.”
As noted in the abstract, physical frailty is not well characterized in breast cancer (BC) and hematopoietic cell transplant (HCT) survivors as a sign of accelerated aging. Its correlation with outcomes and quality of life (QOL) is not defined.
In their paper, researchers Najla El Jurdi, Hok Sreng Te, Qing Cao, Char Napurski, Shuo Wang, Andre Robinson, Mukta Arora, Heba ElHusseini, Fiona He, Laura J. Niedernhofer, Bharat Thyagarajan, Anna Prizment, Shernan Holtan, Anne Hudson Blaes, and Matthew J. Yousefzadeh from the University of Minnesota in Minneapolis; Amgen in Thousand Oaks, CA; and Columbia University Medical Center, in New York, NY conducted a prospective analysis to assess frailty in adult breast cancer and hematopoietic cell transplant survivors. The study aimed to evaluate its impact on QOL and its association with the aging biomarker, p16INK4a.
“…this pilot study demonstrates the alarmingly high prevalence of frailty in two growing cohorts of survivors, those with BC and those undergoing HCT, with detrimental effects of physical functioning, quality of life and overall wellbeing.”
Their data demonstrate the association between frailty and the senescence marker p16INK4a, years after the completion of treatment. These findings further support the need for well-designed senolytic trials in cancer survivors.
Continue reading: DOI: https://doi.org/10.18632/aging.206109
Corresponding Author: Najla El Jurdi – neljurdi@umn.edu
Keywords: aging, hematopoietic cell transplantation, breast cancer, cellular senescence, frailty
Click here to sign up for free Altmetric alerts about this article.
About Aging:
The journal Aging aims to promote 1) treatment of age-related diseases by slowing down aging, 2) validation of anti-aging drugs by treating age-related diseases, and 3) prevention of cancer by inhibiting aging. (Cancer and COVID-19 are age-related diseases.)
Aging is indexed by PubMed/Medline (abbreviated as “Aging (Albany NY)”), PubMed Central, Web of Science: Science Citation Index Expanded (abbreviated as “Aging‐US” and listed in the Cell Biology and Geriatrics & Gerontology categories), Scopus (abbreviated as “Aging” and listed in the Cell Biology and Aging categories), Biological Abstracts, BIOSIS Previews, EMBASE, META (Chan Zuckerberg Initiative) (2018-2022), and Dimensions (Digital Science).
Please visit our website at www.Aging-US.com and connect with us:
- X
- YouTube
- Spotify, and available wherever you listen to podcasts
Click here to subscribe to Aging publication updates.
For media inquiries, please contact media@impactjournals.com.
Aging (Aging-US) Journal Office
6666 E. Quaker St, Suite 1
Orchard Park, NY 14127
Phone: 1-800-922-0957, option 1
Journal
Aging-US
Method of Research
News article
Subject of Research
People
Article Title
Frailty and pre-frailty associated with long-term diminished physical performance and quality of life in breast cancer and hematopoietic cell transplant survivors
Article Publication Date
26-Sep-2024
COI Statement
The authors declare that they have no conflicts of interest.